Mystic Pharmaceuticals Receives U.S. Patent for Intranasal Delivery Technology for Pharmaceuticals and Biologics

AUSTIN, Texas--(BUSINESS WIRE)--
Mystic
Pharmaceuticals, Inc., an integrated specialty pharmaceutical
company, announced today it has been granted U.S. Patent No. 8,377,009,
“Intranasal Cartridge Devices” a novel device technology for delivering
drugs and biologics into the body via the nasal route. This delivery
system is based upon the company’s VersiDoser®
and VRx2™ unit dose packaging and delivery platforms.

Mystic’s President and CEO, Timothy Sullivan stated that, “The US market
for nasal pharmaceuticals is projected to hit $4.25B by 2015 for a broad
range of therapeutic drugs. Nasal vaccines will further expand this
market opportunity for our technology. Our VersiDoser® and VRx2™
delivery solutions are designed to enhance the patient experience by
making these products safer, easier and more convenient to use.”
Applications for the company’s intranasal delivery technology include
vaccines for infectious diseases such as pandemic or seasonal influenza
and therapeutics for pain management, seizure, emesis, depression,
hormone therapy and diabetes.

Mystic’s patient oriented delivery technology, used in combination with
pharmaceutical drugs and biologics, provides the patient a superior
product experience to facilitate
compliance and adherence to prescribed use leading to improved
health outcomes. For manufacturers, developing patient oriented
combination products will benefit the consumer and can extend or
establish market exclusivity and competitive differentiation for new or
existing products. Mystic’s delivery solutions are engineered to meet
the diverse demands of manufacturers and consumers in a globally
competitive market.

Mystic Pharmaceuticals™ is an integrated specialty pharmaceutical
company based in Austin, Texas. Mystic provides patient oriented
delivery solutions for pharmaceuticals, biopharmaceuticals and biologics
for intranasal, ophthalmic, sublingual, and otic applications. Mystic
combines its novel delivery systems with pharmaceuticals and biologics
under development by Mystic and its partners, to meet the expanding
global market demand for healthcare products that are safer, simpler to
use and cost effective. For more information please visit the Mystic
website: www.mysticpharmaceuticals.com.

Mystic Pharmaceuticals, Inc.Melissa Brandt, +(1) 512-918-2900,
ext. 224mbrandt@mysticpharmaceuticals.com

Source: Mystic Pharmaceuticals, Inc.